TY - JOUR T1 - Linear epitope landscape of SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients JF - medRxiv DO - 10.1101/2020.07.13.20152587 SP - 2020.07.13.20152587 AU - Yang Li AU - Ming-liang Ma AU - Qing Lei AU - Feng Wang AU - Dan-yun Lai AU - Hongyan Hou AU - Zhao-wei Xu AU - Bo Zhang AU - Hong Chen AU - Caizheng Yu AU - Jun-biao Xue AU - Yun-xiao Zheng AU - Xue-ning Wang AU - He-wei Jiang AU - Hai-nan Zhang AU - Huan Qi AU - Shu-juan Guo AU - Yandi Zhang AU - Xiaosong Lin AU - Zongjie Yao AU - Jiaoxiang Wu AU - Huiming Sheng AU - Ziyong Sun AU - Xionglin Fan AU - Sheng-ce Tao Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/14/2020.07.13.20152587.abstract N2 - Neutralization antibodies and vaccines for treating COVID-19 are desperately needed. For precise development of antibodies and vaccines, the key is to understand which part of SARS-CoV-2 Spike protein is highly immunogenic on a systematic way. We generate a linear epitope landscape of Spike protein by analyzing serum IgG response of 1,051 COVID-19 patients with a peptide microarray. We reveal two regions that rich of linear epitopes, i.e., CTD and a region close to the S2’ cleavage site and fusion peptide. Unexpectedly, we find RBD is lack of linear epitope. Besides 3 moderate immunogenic peptides from RBD, 16 highly immunogenic peptides from other regions of Spike protein are determined. These peptides could serve as the base for precise development of antibodies and vaccines for COVID-19 on a systematic level.One sentence summary A linear epitope landscape of SARS-CoV-2 Spike protein is generated by analyzing serum IgG response of 1,051 COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by National Key Research and Development Program of China Grant (No. 2016YFA0500600), Science and Technology Commission of Shanghai Municipality (No. 19441911900), Interdisciplinary Program of Shanghai Jiao Tong University (No. YG2020YQ10), National Natural Science Foundation of China (No. 31970130, 31600672, 31670831, and 31370813).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (IRB ID:TJ-C20200128)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe peptide microarray data are deposited on Protein Microarray Database (http://www.proteinmicroarray.cn) http://www.proteinmicroarray.cn ER -